Depression during interferon therapy for chronic viral hepatitis: Early identification of patients at risk by means of a computerized test

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 5, 2000, Pages 505-509

  Scalori, Astrid ^a,c   Apale, Paolo ^a   Panizzuti, Fabio ^a   Mascoli, Nerina ^a   Pioltelli, Pietro ^a   Pozzi, Massimo ^a   Redaelli, Alessandro ^a   Roffi, Luigi ^a,b   Mancia, Giuseppe ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Ospedale Civile   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic viral hepatitis; Depression; Interferon; MMPI

Indexed keywords

RECOMBINANT ALPHA2 INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CORRELATION FUNCTION; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINNESOTA MULTIPHASIC PERSONALITY INVENTORY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0034035903     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012050-00005     Document Type: Article

References (25)

1. 1 Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26(suppl 1):71S-77S.
2. 2 Scott GM, Secher DS, Flowers D, Bate J, Cantell K, Tyrrell DAJ. Toxicity of Interferon. BMJ 1981; 282:1345-1348.
3. 3 Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(3 suppl 1):112S-121S.
4. 4 Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murrayet LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102:2155-2160.
5. 5 Deutsh M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26:206-210.
6. 6 Hoofnagle JH. Thrombocytopenia during interferon alpha therapy [Letter]. JAMA 1991; 266:849.
7. 7 Renauld PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147:1577-1580.
8. 8 McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. Lancet 1987; ii:1175-1178.
9. 9 Fattovich G, Giustina G, Favarato S, Ruol A, and Investigators of the Italian Association for the Study of the Liver. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38-47.
10. 10 Janssen HLA, Brouwer JT, van der Mast R, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241-243.
11. 11 Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938-941.
12. 12 Mosticoni R, Chiari G. Una descrizione obiettiva della personalità. II Minnesota Multiphasic Personality Inventory (MMPI). Firenze, Italy: Organizzazioni Speciali. Rot Off Set, 1993, pp.15-28.
13. 13 Hathaway SR, McKinley JC. Manual for Administration and Scoring of the MMPI. Minneapolis: University of Minnesota Press; 1983.
14. 14 Merimsky O, Chaitchik S. Neurotoxicity of interferon alpha. Anti-Cancer Drugs 1992; 3:567-570.
15. 15 Mattson K, Niiranen A, livanainen M, Färkkilä M, Bergstrom L, Holsti LR, et al. Neurotoxicity of interferon. Cancer Treatment Rep 1983; 67:958-961.
16. 16 Priestman TJ. Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. Lancet 1980; ii:113-118.
17. 17 Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26:596-600.
18. 18 Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA. Central nervous system toxicity of interferon. Br J Cancer 1983; 47:419-422.
19. 19 Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immuno-deficiency virus-1 -infected individuals. J Neuropsychiatr Clin Neurosci 1996; 8:74-81.
20. 20 Bocci V. Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeost Agents 1988; 3:107-118.
21. 21 Winokur G, Clayton PJ (editors). In: The Medical Basis of Psychiatry. Philadelphia: WB Saunders Company; 1994. pp. 47-67.
22. 22 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
23. 23 Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995; 22:135-142.
24. 24 Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141-147.
25. 25 International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351:1535-1539.